Amy Altshul active positions
Companies | Position | Start | End |
---|---|---|---|
GSK PLC | Chief Tech/Sci/R&D Officer | - | - |
General Counsel | - | - | |
Galvani Bioelectronics Ltd.
Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Director/Board Member | 2021-03-23 | - |
Career history of Amy Altshul
Statistics
International
United Kingdom | 3 |
Operational
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
General Counsel | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
GSK PLC | Health Technology |
Private companies | 1 |
---|---|
Galvani Bioelectronics Ltd.
Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Health Technology |
- Stock Market
- Insiders
- Amy Altshul
- Experience